Almost half of cancer patients are diagnosed in late stages

Analysis by Cancer Research UK, released on Monday 22 September, concluded that 46% of cancers in England are diagnosed in the advanced stages. Given the importance of early diagnosis, this would indicates that almost half of cancer patients are diagnosed at a point when treatment will no longer be truly effective. The report, conducted by Incisive Health for CRUK, indicated …

From Cedar and Peanut allergies to Cancer Vaccines and Immunotherapeutics: This is the future of DNA vaccine technology

From Cedar and Peanut allergies to Cancer Vaccines and Immunotherapeutics: This is the future of DNA vaccine technology

One company stands on the brink of a revolution in vaccine technology that has the potential to change millions of lives with innovative DNA and RNA vaccines See the future of DNA vaccines: download the report For over 20 years the vaccines industry has pushed towards the goal of creating an effective DNA vaccine. But thus far the industry has …

Can Gold Fight Cancer?

Exciting developments have gripped the cancer research space as a result of a “Trojan horse” treatment for Glioblastoma Multiforme, an extremely aggressive form of brain cancer which sees a devastating survival rate at just six in every 100 patients making it past the 5-year mark. This form of brain cancer is notorious as adults rarely survive past the first months of diagnosis. …

Lpath Reports Interim Data From Phase 2a Study for Anti-Cancer Drug, ASONEP

July 24, 2014: Lpath, Inc.  the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor …

Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer

July 24, 2014: Celsion Corporation announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC).  The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients enrolled and treated, 10 were eligible for evaluation of …

Marketing Authorisation Makes Life-Extending Treatment for Advanced Breast Cancer Available After Only One Prior Chemotherapy

July 3, 2014: New, earlier use indication for Halaven® (Eribulin) could benefit thousands of women across Europe including women inDenmark, Finland, Norway, and Sweden From today, women with locally advanced or metastatic breast cancer (MBC)  across Europe will have earlier access to Halaven® (Eribulin). In the Nordic countries, Eribulin is now indicated for the treatment of patients with locally advanced or MBC who have progressed after at least one chemotherapeutic …

AbbVie Announces Initiation of Pivotal Phase III Study of Veliparib (ABT-888) in Patients with Advanced Breast Cancer

June 26, 2014:  AbbVie today announced the initiation of a Phase III clinical trial evaluating the safety and efficacy of its investigational compound, veliparib (ABT-888), when added to carboplatin and paclitaxel, two chemotherapeutic medicines, in patients with advanced breast cancer. Specifically, the combination of veliparib, carboplatin and paclitaxel will be compared to treatment with carboplatin, paclitaxel and placebo in patients …

How BINDI – a computer-designed protein – causes cancer cell death

Image: UW Institute for Protein Design A fascinating paper from the UW Institute for Protein Design was released in the scientific journal Cell last week. It described the design and development of a completely new protein which binds and inhibits cancer-causing protein BHRF1. BHRF1 is encoded by the Epstein-Barr virus (EBV) and is responsible for cell growth disruption. EBV is …

Definiens Secures € 15 Million for Tissue Phenomics-based Cancer Diagnostics

June 23 2014: Definiens AG, which offers a unique approach to tissue diagnostics aimed at helping physicians improve treatment, said that it has closed a round of financing for € 15 million. The round was led by Wellington Partners, a leading pan-European venture capital firm. Gilde Healthcare co-led the financing round and was joined by other existing investors Cipio Partners and TVM …

Inovio Pharmaceuticals Initiates Cervical Cancer Clinical Trial

June 23, 2014: Inovio Pharmaceuticals, Inc.  today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity, clinical responses and disease-free survival of its DNA immunotherapy product, INO-3112, in treating human papillomavirus (HPV)-associated cervical cancer. INO-3112 is a combination of Inovio’s lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being …